v3.25.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Cash Flows from Operating Activities:      
Net income $ 1,511,182 $ 1,163,109 $ 719,307
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation & amortization 618,743 584,831 568,041
Stock-based compensation expense 95,688 99,349 87,720
Unrealized gain on non-marketable securities (93,291) 0 0
Loss (gain) on sales of assets and businesses 7,968 (9,920) (6,250)
Costs related to extinguishment of debt 0 3,158 0
Changes in assets & liabilities, net of effects from acquisitions and dispositions:      
Accounts receivable (317,985) 67,355 (182,444)
Accrued interest (4,053) 12,814 1,193
Accrued and deferred income taxes (21,441) 12,651 (43,450)
Other working capital accounts 99,189 61,897 (32,321)
Other assets and deferred charges (28,599) (12,163) 48,517
Other, net 19,700 21,811 39,133
Accrued insurance expense, net of commercial premiums paid 236,771 254,394 183,462
Payments made in settlement of self-insurance claims, net of commercial insurance reimbursements (259,475) (192,185) (118,089)
Deferred grant revenue 0 0 2,978
Net cash provided by operating activities 1,864,397 2,067,101 1,267,797
Cash Flows from Investing Activities:      
Property and equipment additions (1,015,152) (943,810) (743,055)
Proceeds received from sales of assets and businesses 15,863 38,563 24,187
Acquisition of businesses and property (47,804) (18,998) (3,728)
(Outflows) inflows from foreign exchange contracts that hedge our net U.K. investment. (52,213) 12,860 (40,695)
Costs incurred for purchase and development of enterprise resource planning application (24,695) 0 0
Proceeds received from sale of marketable equity securities 63,073 0 0
Investments in non-marketable securities (9,831) 0 0
Decrease in capital reserves of commercial insurance subsidiary 142 276 16
Net cash used in investing activities (1,070,617) (911,109) (763,275)
Cash Flows from Financing Activities:      
Repayments of long-term debt (43,504) (2,640,001) (85,480)
Additional borrowings 285,536 2,210,248 185,100
Financing costs (382) (12,566) (308)
Repurchase of common shares (967,951) (670,754) (547,363)
Dividends paid (51,267) (53,346) (55,480)
Issuance of common stock 16,729 15,070 13,654
Profit distributions to noncontrolling interests (11,734) (6,508) (6,830)
Purchase of ownership interests by minority members 22,846 12,980 2,762
Net cash used in financing activities (749,727) (1,144,877) (493,945)
Effect of exchange rate changes on cash and cash equivalents 2,517 (833) 3,056
Increase in cash, cash equivalents and restricted cash 46,570 10,282 13,633
Cash, cash equivalents and restricted cash, beginning of period 224,752 214,470 200,837
Cash, cash equivalents and restricted cash, end of period 271,322 224,752 214,470
Supplemental Disclosures of Cash Flow Information:      
Interest paid 156,041 168,274 200,446
Income taxes paid, net of refunds 470,865 325,430 257,896
Noncash purchases of property and equipment $ 74,423 $ 118,109 $ 66,899